Clinical Trial Update: CLAG-GO for Patients With Persistent, Relapsed or Refractory AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the CLAG-GO regimen in adults with persistent, relapsed, or refractory acute myeloid leukemia, currently recruiting (NCT040502…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aclarubicin (aclarubicin)
• CYTARABINE (CYTARABINE)
• Filgrastim (filgrastim)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent | Phase 2 | Status: RECRUITING